Crossmark

Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975–2022 with insights on the impact of COVID-19

Published Online: 2025-01-16

Published Print: 2025-02

Authors

Yamamoto, Hiroki

Shirasawa, Masayuki https://orcid.org/0000-0002-9401-6286
Naoki, Katsuhiko
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Received: 3 December 2024

Accepted: 5 January 2025

First Online: 16 January 2025

Declarations

:

: Dr. Yamamoto has nothing to disclose. Dr. Shirasawa reports personal fees from MSD, personal fees from Asahi Kasei, personal fees from AstraZeneca.K.K, personal fees from Ono, personal fees from BMS, personal fees from Chugai, personal fees from Eli Lilly, personal fees from Daiichi Sankyo, outside the submitted work; . Dr. Naoki reports personal fees from AstraZeneca.K.K, personal fees from BMS, grants and personal fees from Chugai, grants and personal fees from Nippon Boehringer Ingelheim, grants from ONO, grants from Taiho , grants from PAREXEL, outside the submitted work; .

Document is current